{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-240585","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.699219+00:00","generated_at":"2026-05-30T11:37:08.397040+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Annexon reports Phase 2 ANX007 data: 0% vision loss in less advanced GA vs 17% sham","bullets":["ANX007 monthly-treated patients with less advanced dry AMD lost 0% (0/56) 15+ letters vs 17% (10/59) sham (p=0.0013).","In overall Phase 2 ARCHER, ANX007 monthly reduced 15+ letter loss to 6% (5/89) vs 21% (19/89) sham (p=0.0021).","ANX007 showed 61% decrease in EZ loss in patients with <80% EZ intact at baseline (p=0.0575).","Pivotal Phase 3 ARCHER II data expected in second half 2026.","ANX007 is a first-in-kind Fab targeting C1q intravitreally; data presented at AAO 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-240585","json":"https://secwatch.observer/filing/0001193125-24-240585.json","markdown":"https://secwatch.observer/filing/0001193125-24-240585.md","text":"https://secwatch.observer/filing/0001193125-24-240585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524240585/0001193125-24-240585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524240585/d849436d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:37:08.397040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}